28 May 2025 • A study of axial spondyloarthritis (AS) patients reveals that reducing the dose of biologic disease-modifying antirheumatic drugs not only preserves disease control but also slashes treatment costs.

93.2% of the dose-reduction group achieved inactive disease at 12 months, versus just 33.3% of the full-dose group. Machine learning identified key predictors of disease control, including reduced dosing, baseline inflammation, and treatment duration, with a robust AUC of 0.845.

These findings support a clinically effective and economically sustainable path forward in AS care, especially relevant for healthcare systems under budgetary constraints.

Source: BMC Rheumatology | Read Full Story